Robot
26.Mar.25 12:25 PM

Perplexity Challenges Google's AdWords Revenue with Native Transactions and Structured Responses

Perplexity, a rising AI search engine backed by Amazon and Nvidia, is challenging Google's dominance by introducing native transactions and structured responses for specific verticals, aiming to compete for the lucrative AdWords revenue. This development comes as Alphabet reports that its AI-powered search features are generating revenue at similar rates to traditional search results, highlighting the growing competition in the AI search mark...
Robot
26.Mar.25 12:15 PM

GameStop Surges in Pre-Market Trading After Beating Earnings Estimates

GameStop shares experienced a significant jump in pre-market trading today, fueled by the company's better-than-expected fourth-quarter earnings report. Although revenue fell short of analyst estimates, the video game retailer's adjusted earnings per share of 30 cents significantly surpassed the anticipated eight cents, leading to a surge in investor optimism and a subsequent rise in stock price.
Robot
26.Mar.25 12:04 PM

Analysts Anticipate $1.48 EPS, $1.51 Billion Revenue, with Mixed Analyst Ratings and Price Targets

Paychex, Inc. (PAYX) is expected to report third-quarter earnings of $1.48 per share on Wednesday, March 26, with analysts projecting quarterly revenue of $1.51 billion. Several analysts have provided their ratings and price targets for Paychex, with Barclays maintaining an Equal-Weight rating and RBC Capital reiterating a Sector Perform rating.
Robot
26.Mar.25 11:59 AM

Vietnam Approves Starlink Trial, Eyes Digital Divide and Tariffs

Vietnam has approved a trial launch of SpaceX's Starlink satellite internet service until the end of 2030, aiming to bridge the digital divide and potentially avoid U.S. tariffs. This move comes as SpaceX prepares to launch a new Starlink dish offering gigabit internet speeds, further bolstering its global internet service expansion.
Robot
26.Mar.25 11:57 AM

Humacyte Stock Tumbles After Public Offering Announcement, Raising Dilution Concerns

Humacyte Inc. (HUMA) shares plummeted in after-hours trading on Tuesday following the announcement of a public offering, with the company aiming to utilize the proceeds for commercializing SYMVESS and developing other product candidates. The stock price dropped by 21.39%, reaching $2.26 at the time of publication, likely due to investor concerns about potential share dilution.